BackNeumora Therapeutics Overview
Neumora Therapeutics Inc.

Neumora Therapeutics Target Price

Analysts' average 12-month price target for Neumora Therapeutics is $4.5.

Get informed when a big investor buys or sells

+ Follow

Share Price

$0.73

Average Target Price

$4.50516.4% upside

2 analysts in the last 4 months

High: $5 | Low: $4

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-13RBC CapitalBrian Abrahams$5584.9% upsideOpen
2026-06-18Mizuho Securities$4447.9% upsideOpen
2026-01-12Leerink PartnersMarc Goodman$8995.9% upsideOpen
2026-01-05Mizuho SecuritiesGraig Suvannavejh$6721.9% upsideOpen
2025-12-01RBC Capital$7858.9% upsideOpen
2025-10-28Needham$8995.9% upsideOpen
2025-03-07Stifel Nicolaus$2174% upsideOpen
2025-01-02RBC CapitalBrian Abrahams$4447.9% upsideOpen
2024-07-22NeedhamAmi Fadia$233050.7% upsideOpen
2024-07-08Mizuho SecuritiesGraig Suvannavejh$202639.7% upsideOpen
2024-06-17RBC CapitalBrian Abrahams$293872.6% upsideOpen
2024-03-13RBC CapitalBrian Abrahams$314146.6% upsideOpen
2023-10-10Stifel NicolausPaul Matteis$263461.6% upsideOpen
2023-10-10RBC CapitalBrian Abrahams$243187.7% upsideOpen

Neumora Therapeutics (NMRA) FAQ

Neumora Therapeutics (NMRA) currently reports a target price of $4.5. Use the charts on this page to explore Neumora Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Neumora Therapeutics is $4.5, about 516.4% upside from the current share price of $0.73. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $4.5, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neumora Therapeutics, and consider following NMRA for alerts when major investors trade the stock.